The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke - II

Neurologic outcome and efficacy analysis

Yuko Y. Palesch, Michael D. Hill, Karla J. Ryckborst, Diego Tamariz, Myron Ginsberg

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE - High-dose human albumin (ALB) is robustly neuroprotective in rodent stroke models. A phase I dose-escalation study was conducted to assess the safety of ALB therapy in ischemic stroke. We analyzed the data for preliminary evidence of treatment efficacy. METHODS - Eighty-two subjects with acute ischemic stroke (NIH Stroke Scale [NIHSS] of 6 or above) received 25% ALB beginning within 16 hours of stroke onset. Six successive ALB dose tiers were assessed (range, 0.34 to 2.05 g/kg). Forty-two patients also received standard-of-care intravenous tissue plasminogen activator (tPA). Efficacy outcomes were determined at 3 months. We compared the highest three, putatively therapeutic ALB dose tiers (1.37 to 2.05 g/kg) with the lowest three, presumed subtherapeutic doses (0.34 to 1.03 g/kg) and with historical cohort data derived from the NINDS rt-PA Stroke Study. RESULTS - After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57). The tPA-treated subjects who received higher-dose ALB were three times more likely to achieve a good outcome than subjects receiving lower-dose ALB, suggesting a positive synergistic effect between ALB and tPA. CONCLUSIONS - Our data suggest that high-dose ALB therapy may be neuroprotective after ischemic stroke. These results have led to a multicenter, randomized, placebo-controlled efficacy trial of ALB in acute ischemic stroke-the ALIAS Phase III Trial.

Original languageEnglish
Pages (from-to)2107-2114
Number of pages8
JournalStroke
Volume37
Issue number8
DOIs
StatePublished - Aug 1 2006

Fingerprint

Nervous System
Albumins
Stroke
Safety
Tissue Plasminogen Activator
National Institute of Neurological Disorders and Stroke
Therapeutics
Confidence Intervals
Standard of Care
Rodentia
Cohort Studies
Placebos

Keywords

  • Ischemia
  • Neuroprotection
  • Outcome
  • Stroke
  • Thrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke - II : Neurologic outcome and efficacy analysis. / Palesch, Yuko Y.; Hill, Michael D.; Ryckborst, Karla J.; Tamariz, Diego; Ginsberg, Myron.

In: Stroke, Vol. 37, No. 8, 01.08.2006, p. 2107-2114.

Research output: Contribution to journalArticle

Palesch, Yuko Y. ; Hill, Michael D. ; Ryckborst, Karla J. ; Tamariz, Diego ; Ginsberg, Myron. / The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke - II : Neurologic outcome and efficacy analysis. In: Stroke. 2006 ; Vol. 37, No. 8. pp. 2107-2114.
@article{3ba65c39ad834268bd7854526fa91e9b,
title = "The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke - II: Neurologic outcome and efficacy analysis",
abstract = "BACKGROUND AND PURPOSE - High-dose human albumin (ALB) is robustly neuroprotective in rodent stroke models. A phase I dose-escalation study was conducted to assess the safety of ALB therapy in ischemic stroke. We analyzed the data for preliminary evidence of treatment efficacy. METHODS - Eighty-two subjects with acute ischemic stroke (NIH Stroke Scale [NIHSS] of 6 or above) received 25{\%} ALB beginning within 16 hours of stroke onset. Six successive ALB dose tiers were assessed (range, 0.34 to 2.05 g/kg). Forty-two patients also received standard-of-care intravenous tissue plasminogen activator (tPA). Efficacy outcomes were determined at 3 months. We compared the highest three, putatively therapeutic ALB dose tiers (1.37 to 2.05 g/kg) with the lowest three, presumed subtherapeutic doses (0.34 to 1.03 g/kg) and with historical cohort data derived from the NINDS rt-PA Stroke Study. RESULTS - After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81{\%} greater than in the lower dose-tiers (relative risk [RR], 1.81; 95{\%} confidence interval [CI], 1.11 to 2.94) and was 95{\%} greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95{\%} CI, 1.47 to 2.57). The tPA-treated subjects who received higher-dose ALB were three times more likely to achieve a good outcome than subjects receiving lower-dose ALB, suggesting a positive synergistic effect between ALB and tPA. CONCLUSIONS - Our data suggest that high-dose ALB therapy may be neuroprotective after ischemic stroke. These results have led to a multicenter, randomized, placebo-controlled efficacy trial of ALB in acute ischemic stroke-the ALIAS Phase III Trial.",
keywords = "Ischemia, Neuroprotection, Outcome, Stroke, Thrombolysis",
author = "Palesch, {Yuko Y.} and Hill, {Michael D.} and Ryckborst, {Karla J.} and Diego Tamariz and Myron Ginsberg",
year = "2006",
month = "8",
day = "1",
doi = "10.1161/01.STR.0000231389.34701.b5",
language = "English",
volume = "37",
pages = "2107--2114",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke - II

T2 - Neurologic outcome and efficacy analysis

AU - Palesch, Yuko Y.

AU - Hill, Michael D.

AU - Ryckborst, Karla J.

AU - Tamariz, Diego

AU - Ginsberg, Myron

PY - 2006/8/1

Y1 - 2006/8/1

N2 - BACKGROUND AND PURPOSE - High-dose human albumin (ALB) is robustly neuroprotective in rodent stroke models. A phase I dose-escalation study was conducted to assess the safety of ALB therapy in ischemic stroke. We analyzed the data for preliminary evidence of treatment efficacy. METHODS - Eighty-two subjects with acute ischemic stroke (NIH Stroke Scale [NIHSS] of 6 or above) received 25% ALB beginning within 16 hours of stroke onset. Six successive ALB dose tiers were assessed (range, 0.34 to 2.05 g/kg). Forty-two patients also received standard-of-care intravenous tissue plasminogen activator (tPA). Efficacy outcomes were determined at 3 months. We compared the highest three, putatively therapeutic ALB dose tiers (1.37 to 2.05 g/kg) with the lowest three, presumed subtherapeutic doses (0.34 to 1.03 g/kg) and with historical cohort data derived from the NINDS rt-PA Stroke Study. RESULTS - After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57). The tPA-treated subjects who received higher-dose ALB were three times more likely to achieve a good outcome than subjects receiving lower-dose ALB, suggesting a positive synergistic effect between ALB and tPA. CONCLUSIONS - Our data suggest that high-dose ALB therapy may be neuroprotective after ischemic stroke. These results have led to a multicenter, randomized, placebo-controlled efficacy trial of ALB in acute ischemic stroke-the ALIAS Phase III Trial.

AB - BACKGROUND AND PURPOSE - High-dose human albumin (ALB) is robustly neuroprotective in rodent stroke models. A phase I dose-escalation study was conducted to assess the safety of ALB therapy in ischemic stroke. We analyzed the data for preliminary evidence of treatment efficacy. METHODS - Eighty-two subjects with acute ischemic stroke (NIH Stroke Scale [NIHSS] of 6 or above) received 25% ALB beginning within 16 hours of stroke onset. Six successive ALB dose tiers were assessed (range, 0.34 to 2.05 g/kg). Forty-two patients also received standard-of-care intravenous tissue plasminogen activator (tPA). Efficacy outcomes were determined at 3 months. We compared the highest three, putatively therapeutic ALB dose tiers (1.37 to 2.05 g/kg) with the lowest three, presumed subtherapeutic doses (0.34 to 1.03 g/kg) and with historical cohort data derived from the NINDS rt-PA Stroke Study. RESULTS - After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57). The tPA-treated subjects who received higher-dose ALB were three times more likely to achieve a good outcome than subjects receiving lower-dose ALB, suggesting a positive synergistic effect between ALB and tPA. CONCLUSIONS - Our data suggest that high-dose ALB therapy may be neuroprotective after ischemic stroke. These results have led to a multicenter, randomized, placebo-controlled efficacy trial of ALB in acute ischemic stroke-the ALIAS Phase III Trial.

KW - Ischemia

KW - Neuroprotection

KW - Outcome

KW - Stroke

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=33747155340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747155340&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000231389.34701.b5

DO - 10.1161/01.STR.0000231389.34701.b5

M3 - Article

VL - 37

SP - 2107

EP - 2114

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -